Clinical Report: Risk Assessment Framework for Cardiovascular Disease in r-axSpA

Overview

This study developed a risk stratification model for cardiovascular disease (CVD) in patients with radiographic axial spondyloarthritis (r-axSpA) using four independent predictors. The model demonstrated excellent discriminative ability and clinical utility, highlighting the importance of routine clinical variables in predicting CVD risk.

Background

Patients with radiographic axial spondyloarthritis (r-axSpA) are at an increased risk for cardiovascular disease (CVD), which can significantly impact their health outcomes. Despite this elevated risk, there are limited practical tools available for clinicians to predict CVD in this population. Developing a reliable risk assessment framework is crucial for early identification and management of CVD in r-axSpA patients.

Data Highlights

Key Findings

• Four independent predictors of CVD in r-axSpA patients were identified: age, hypertension, diabetes mellitus, and alkaline phosphatase (ALP).
• The model achieved an AUC of 0.888 in the training set, indicating excellent discriminative ability.
• In the validation set, the model maintained an acceptable AUC of 0.741.
• Calibration of the model was satisfactory with a Brier score of 0.115.
• Decision curve analysis confirmed a positive net benefit of the model.
• Subgroup analysis indicated robust performance across both sexes.

Clinical Implications

The developed risk stratification model provides clinicians with a practical tool for identifying r-axSpA patients at high risk for CVD using readily available clinical data. Implementing this model could enhance early intervention strategies and improve patient outcomes in this high-risk population.

Conclusion

The study presents a simple and effective risk assessment tool for CVD in r-axSpA patients, emphasizing the need for external validation before clinical implementation. This model could significantly aid in the management of cardiovascular risks in this patient group.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Clinical Rheumatology, 2023 -- Evaluating Cardiovascular Risks in Axial Spondyloarthritis: A Comprehensive Review
3. Clinical Rheumatology, 2026 -- Prevalence and risk factors of difficult-to-treat axial spondyloarthritis: Real-life evidence from the BioSTaR database
4. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update | Annals of the Rheumatic Diseases
5. Clinical Rheumatology — Challenges in diagnosing and monitoring radiographic and non-radiographic axial spondyloarthritis in daily clinical practice
6. Frontiers | Cardiovascular involvement in ankylosing spondylitis and axial spondyloarthritis: epidemiology, mechanisms, and clinical management
7. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update | Annals of the Rheumatic Diseases
8. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials - PMC